Latest news with #ConcertAI
Yahoo
31-05-2025
- Business
- Yahoo
ConcertAI Provides Intelligent Automation of ASCO® Guidelines into its Generative and Agentic AI Precision Suite™ and CancerLinQ® SmartLinQ™ Solutions
Powered by CARAai, ASCO® Guideline-concordant care recommendations will be automatically provided to CancerLinQ Network medical oncologists through SmartLinQ, and for biopharma research through Precision Explorer and Trials CAMBRIDGE, Mass., May 31, 2025--(BUSINESS WIRE)--ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the integration of the American Society of Clinical Oncology® (ASCO®) Guidelines through the CARAai platform for its Precision Suite and CancerLinQ® SmartLinQ solutions™. Now, the power of the Precision Suite's low-latency and high-recency data can be used by biopharma researchers to assess Guideline-concordant care and outcomes at any point in time or reviewing changes over time. Members of the CancerLinQ® network using SmartLinQ solutions will now have ASCO Guideline-concordant recommendations for their individual patients as an augmentation of their assessment of treatment options. This published information will be integrated with other SmartLinQ features that can help oncologists consider a complete set of treatment options for optimized patient outcomes. In December of 2023, ASCO and ConcertAI announced the acquisition of CancerLinQ and ongoing network operations as a ConcertAI initiative. Over the last year and a half, ConcertAI has advanced the SmartLinQ application for QOPI® applications as well as advanced notifications of potentially beneficial diagnostics and newly approved therapeutics for a provider's patients. SmartLinQ works directly within the workflows of Epic and other EMRs. ASCO Guidelines will be augmenting the SmartLinQ solution by June 15th as part of the company's effort to assure that all network practices have that informational resource. On May 30th, ConcertAI announced its oncology Precision Suite™ of generative and agentic AI solutions for advancing analytics and inferences, and for clinical trial design and optimization. The ASCO Guidelines will be available within these solutions by June 30th for assessment of Guideline-concordant care across the widest array of settings, and to inform the design of clinical trial controls according to published clinical recommendations. "Through CancerLinQ, ConcertAI has an almost decade-long history of collaborating with ASCO," said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. "This license of ASCO Guidelines represents a new opportunity to harness the latest generative and agentic AI technologies to promote high-quality cancer care, evidence generation, and advanced care insights." The CancerLinQ SmartLinQ deployment of these guidelines will be available to demonstrate at the 2025 ASCO Annual Meeting in Chicago. About ConcertAI: ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at View source version on Contacts Media ContactTreble McKenzie Covellconcertai@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
31-05-2025
- Business
- Business Wire
ConcertAI Provides Intelligent Automation of ASCO ® Guidelines into its Generative and Agentic AI Precision Suite™ and CancerLinQ ® SmartLinQ™ Solutions
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the integration of the American Society of Clinical Oncology® (ASCO®) Guidelines through the CARAai platform for its Precision Suite and CancerLinQ® SmartLinQ solutions™. Now, the power of the Precision Suite's low-latency and high-recency data can be used by biopharma researchers to assess Guideline-concordant care and outcomes at any point in time or reviewing changes over time. Members of the CancerLinQ® network using SmartLinQ solutions will now have ASCO Guideline-concordant recommendations for their individual patients as an augmentation of their assessment of treatment options. This published information will be integrated with other SmartLinQ features that can help oncologists consider a complete set of treatment options for optimized patient outcomes. In December of 2023, ASCO and ConcertAI announced the acquisition of CancerLinQ and ongoing network operations as a ConcertAI initiative. Over the last year and a half, ConcertAI has advanced the SmartLinQ application for QOPI® applications as well as advanced notifications of potentially beneficial diagnostics and newly approved therapeutics for a provider's patients. SmartLinQ works directly within the workflows of Epic and other EMRs. ASCO Guidelines will be augmenting the SmartLinQ solution by June 15th as part of the company's effort to assure that all network practices have that informational resource. On May 30 th, ConcertAI announced its oncology Precision Suite™ of generative and agentic AI solutions for advancing analytics and inferences, and for clinical trial design and optimization. The ASCO Guidelines will be available within these solutions by June 30 th for assessment of Guideline-concordant care across the widest array of settings, and to inform the design of clinical trial controls according to published clinical recommendations. 'Through CancerLinQ, ConcertAI has an almost decade-long history of collaborating with ASCO,' said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. 'This license of ASCO Guidelines represents a new opportunity to harness the latest generative and agentic AI technologies to promote high-quality cancer care, evidence generation, and advanced care insights.' The CancerLinQ SmartLinQ deployment of these guidelines will be available to demonstrate at the 2025 ASCO Annual Meeting in Chicago. About ConcertAI: ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at
Business Wire
30-05-2025
- Business
- Business Wire
ConcertAI Launches New Generative and Agentic AI-Powered Precision Suite™ Accelerating Oncology Insights and Actions for Healthcare and Life Sciences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ConcertAI, a leader in oncology-focused generative and agentic AI solutions, today announced the launch of its new Precision Suite™. This groundbreaking family of AI-powered solutions redefines the way life sciences and healthcare organizations achieve actionable insights, optimize clinical trials, accelerate in-market execution, and drive improved patient outcomes while saving millions in cost. Powered by ConcertAI's proprietary CARAai™ platform and the unparalleled depth of its integrated Oncology Data, the Precision Suite delivers rapid, persona-tailored insights and enterprise-wide value. The Precision Suite leverages CARAai's multi-modal, AI-curated data architecture to translate complex medical and genomic data into precise, real-world applications. These applications are built on a unique platform that is comprised of assistants, agents, LLMs and LRMs that are specifically designed and trained to support use cases in life sciences and healthcare. Its seamless integration of diverse data types enables life sciences teams to respond faster, make evidence-backed decisions, and maximize strategic impact. At launch, the suite includes three powerful applications tailored to distinct use cases across the healthcare ecosystem. Precision Explorer™ empowers Health Economics and Outcomes Research (HEOR), epidemiology, and medical teams to uncover actionable insights within minutes. Generative AI and intuitive interfaces streamline cohort creation, outcomes analysis, and hypothesis testing, unlocking insights 2x faster than traditional methods, saving customers millions. With its ability to leverage curated oncology data and align with industry guidelines, such as ASCO® Standards, Precision Explorer ensures high-quality, citation-backed results. Precision Trials™ transforms clinical trial operations by enabling smarter, faster decisions in study design, site selection, and patient recruitment. Powered by dynamic AI agents, this solution reduces costly trial amendments, improves site performance, and ensures diversity and enrollment goals are met. CARAai's advanced data-processing capabilities provide real-time assessments, shortening trial timelines with the potential to deliver $4M+ in cost savings for Phase II and III studies. Precision GTM™ focuses on commercialization strategies for oncology therapies, unifying fragmented clinical, claims, and social determinants of health data. Harnessing CARAai's multi-modal insights, this platform enables brand teams to track the real-time standard of care, physician trends, and treatment pathways. By accelerating decision-making and enabling timely engagement, Precision GTM empowers teams to achieve faster, more impactful market execution while generating up to $7M in value for a typical oncology brand. Precision360™, the backbone of ConcertAI's Precision Suite™, integrates EMR and genomic data alongside claims and social determinants of health information to create a revolutionary new RWD dataset. With AI-curation and a recency of less than a week, it provides real-time access to actionable insights, eliminating delays in oncology research and decisions. Designed for speed and efficiency, Precision360 provides accuracy and reliability, even in complex, unstructured datasets. 'Precision Suite is a testament to our commitment to innovation and patient-first outcomes,' said Eron Kelly, CEO of ConcertAI. 'Its ability to process complex, diverse datasets in near real-time has allowed us to deliver immediately actionable insights that will save customers millions in costs, while accelerating their time to market for life saving therapeutics. These new SaaS products are all built on our CARAai platform, the leading agentic AI platform built specifically for the needs of the life sciences enterprise.' 'ConcertAI serves 75% of the top life science companies and more than 50% of the largest global healthcare providers,' said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. 'This launch signifies the evolution of ConcertAI from providing specialized solutions to delivering enterprise-class SaaS tools. Precision Suite aligns our expertise with our mission to deliver scalable, impactful solutions that redefine what's possible in life sciences and healthcare today.' Precision Explorer™ and Precision Trials™ will be available beginning June 30, 2025. Precision GTM™ will follow with availability by July 31, 2025. With these solutions, ConcertAI solidifies its position as the leader in generative and agentic AI tailored for oncology and broader life sciences applications. About ConcertAI: ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at
Yahoo
14-05-2025
- Business
- Yahoo
Artificial Intelligence (AI) in Clinical Trials Market Insights, Competitive Landscape, and Forecasts Report 2025-2032 Featuring Key Players Such as TEMPUS, NetraMark, ConcertAI, AiCure, and Oracle
The AI in Clinical Trials Market is driven by the surge in chronic diseases and increased pharma collaborations. Valued at $1.35 billion in 2024, it aims to reach $3.33 billion by 2032. North America leads due to investment in R&D and numerous trials. Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI) in Clinical Trials - Market Insights, Competitive Landscape, and Market Forecast - 2032" has been added to offering. The Artificial Intelligence (AI) in clinical trials market is projected to experience robust growth from USD 1.35 billion in 2024 to USD 3.33 billion by 2032, reflecting a compound annual growth rate (CAGR) of 12.04% from 2025 to 2032. This expansion is largely driven by the increasing global burden of chronic diseases including diabetes, cancer, and cardiovascular conditions, alongside significant investments in drug discovery and development. AI integration in clinical trials, particularly through software and services, has become crucial. Key technological advancements such as machine learning (ML) and natural language processing (NLP) are pivotal in optimizing trial design, patient recruitment, and site monitoring. As pharmaceutical and biotechnology companies enhance research collaborations, AI-powered solutions significantly streamline processes, expediting drug development. According to recent data, about 518,210 clinical trials were reported globally by December 2024, up from prior years, thus necessitating effective AI tools for administration and data management. Increasing R&D investments, such as the $276 billion in biopharmaceutical R&D noted by PhRMA in 2022, amplify the demand for AI-driven clinical trial solutions. Notably, the product segment of AI in clinical trials, particularly software, is set to hold a significant revenue share by 2024. AI software, crucial for developing, optimizing trial protocols, and managing data, allows efficient patient matching and trial simulation. This innovation is further evidenced by developments like Risklick's Protocol AI and ConcertAI's CTO 2.0, enhancing trial efficacy and reducing costs. North America is expected to dominate the AI in clinical trials market. Contributing factors include a rising prevalence of chronic diseases, significant R&D investments, and an increase in clinical trials. Data-driven insights facilitate better patient recruitment and trial outcomes, further propelled by technological advancements like Phesi's Trial Accelerator and H1's GenosAI tool. Key market players such as TEMPUS, NetraMark, ConcertAI, AiCure, and Oracle are pivotal to the market landscape. Recently, Suvoda introduced the AI-powered assistant Sofia, and Lokavant launched SpectrumT, driving operational efficiencies in trial management. These innovations, among others, showcase the dynamic developments in the AI in clinical trials sector. Despite promising growth prospects, challenges like patient data privacy and AI integration complexities remain. However, the trend towards strategic partnerships and technological advancements continues to propel market growth. The comprehensive AI in clinical trials market report encapsulates industry projections till 2032, highlighting lucrative opportunities and regional insights, especially within top-performing segments and regions like North America. Stakeholders across sectors, including research organizations, start-ups, and government entities, can leverage these insights for strategic growth and innovation in clinical trials. Key Topics Covered: 1. Artificial Intelligence (AI) in Clinical Trials Market Report Introduction 2. Artificial Intelligence (AI) in Clinical Trials Market Executive Summary 3. Competitive Landscape 4. Regulatory Analysis 5. Artificial Intelligence (AI) in Clinical Trials Market Key Factors Analysis 5.1. AI in Clinical Trials Market Drivers 5.2. AI in Clinical Trials Market Restraints and Challenges 5.3. AI in Clinical Trials Market Opportunities 6. Artificial Intelligence (AI) in Clinical Trials Market Porter's Five Forces Analysis 7. Artificial Intelligence (AI) in Clinical Trials Market Assessment 7.1. By Product 7.2. By Technology 7.3. By Application 7.4. By Therapeutic Area 7.5. By End-User 7.6. By Geography 8. Artificial Intelligence (AI) in Clinical Trials Market Company and Product Profiles 9. KOL Views Companies Featured TEMPUS NetraMark ConcertAI AiCure Medpace, Inc. ICON plc Charles River Laboratories Dassault Systemes Oracle Certara Cytel Inc. Phesi DeepHealth Inc. H1 TrialX Suvoda LLC Risklick Lokavant Research Solutions For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
07-05-2025
- Business
- Business Upturn
Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032
By GlobeNewswire Published on May 7, 2025, 22:00 IST New York, USA, May 07, 2025 (GLOBE NEWSWIRE) — Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032 | DelveInsight The demand for AI in clinical trials is experiencing strong growth, primarily fueled by the rising global prevalence of chronic illnesses like diabetes, cardiovascular diseases, respiratory conditions, and cancer. This growth is further bolstered by increasing investments and funding dedicated to enhancing drug discovery and development. Additionally, the expanding trend of strategic alliances and partnerships among pharmaceutical, biotechnology, and medical device firms is significantly contributing to the accelerated adoption of AI-driven clinical trial technologies. DelveInsight's AI in Clinical Trials Market Insights report provides the current and forecast market analysis, individual leading AI in clinical trials companies' market shares, challenges, AI in clinical trials market drivers, barriers, trends, and key market AI in clinical trials companies in the market. Key Takeaways from the AI in Clinical Trials Market Report As per DelveInsight estimates, North America is anticipated to dominate the global AI in clinical trials market during the forecast period. In the product segment of the AI in clinical trials market, the software category had a significant revenue share in 2024. Notable AI in clinical trials companies such as TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, and several others are currently operating in the AI in clinical trials market. and several others are currently operating in the AI in clinical trials market. In March 2025, Suvoda launched Sofia, an AI-powered assistant designed to streamline clinical trial management. Built to support study teams, Sofia simplifies access to and review of critical trial information by delivering intelligent, real-time insights. This innovation enhances operational efficiency, reduces manual workload, and empowers teams to make faster, data-driven decisions throughout the trial lifecycle. launched Sofia, an AI-powered assistant designed to streamline clinical trial management. Built to support study teams, Sofia simplifies access to and review of critical trial information by delivering intelligent, real-time insights. This innovation enhances operational efficiency, reduces manual workload, and empowers teams to make faster, data-driven decisions throughout the trial lifecycle. In December 2024, ConcertAI and NeoGenomics announced the launch of CTO-H, a next-generation AI software solution for research analytics, clinical trial design, and operational optimization. CTO-H delivers an unparalleled research data platform, offering unmatched scale, longitudinal patient insights, and deep biomarker data, enabling more precise, efficient, and data-driven clinical development strategies. announced the launch of CTO-H, a next-generation AI software solution for research analytics, clinical trial design, and operational optimization. CTO-H delivers an unparalleled research data platform, offering unmatched scale, longitudinal patient insights, and deep biomarker data, enabling more precise, efficient, and data-driven clinical development strategies. In June 2024, Lokavant launched Spectrum™, the first AI-driven clinical trial feasibility solution designed to optimize trial performance across the entire clinical development value chain. Spectrum empowers study teams to predict, manage, and optimize trial timelines and costs in real-time. To read more about the latest highlights related to the AI in clinical trials market, get a snapshot of the key highlights entailed in the Global AI in Clinical Trials Market Report AI in Clinical Trials Overview Artificial intelligence (AI) is revolutionizing clinical trials by enhancing efficiency, accuracy, and patient outcomes across the entire trial lifecycle. AI-powered tools enable faster patient recruitment by analyzing electronic health records and identifying eligible candidates based on complex inclusion and exclusion criteria. This targeted approach reduces trial enrollment time and improves diversity among participants. Additionally, AI can optimize trial design by simulating outcomes using real-world data, allowing researchers to refine protocols and predict potential risks, ultimately leading to more robust and reliable results. Moreover, AI facilitates real-time monitoring and data analysis during trials, enabling early detection of adverse events and anomalies. Machine learning algorithms can process vast amounts of data from wearable devices, lab results, and patient-reported outcomes to identify patterns that might be overlooked by traditional methods. This enhances decision-making and allows for adaptive trial designs, where protocols can be modified in response to interim findings. As regulatory bodies grow more comfortable with AI-driven methodologies, the integration of AI in clinical trials holds the promise of accelerating drug development while ensuring safety and efficacy. AI in Clinical Trials Market Insights North America held the largest share of the AI in clinical trials market in 2024. This leading position is driven by several key factors, including the increasing burden of chronic diseases, substantial R&D investments, and a growing volume of clinical trials in the region. The market is also benefiting from the rise in research collaborations and strategic partnerships among pharmaceutical and medical device companies, alongside the continuous development of sophisticated AI technologies. Major players in the North American market are making significant R&D investments to develop cutting-edge AI tools aimed at streamlining clinical trials. For instance, in October 2022, Phesi introduced its AI-driven Trial Accelerator platform, which enhances clinical trial planning through real-time scenario analysis. Utilizing the world's most comprehensive clinical trial database, this SaaS platform helps optimize patient recruitment, endpoint determination, country selection, and site allocation—boosting trial efficiency and outcomes. Likewise, in October 2023, H1 launched GenosAI, a generative AI feature integrated into its Trial Landscape platform. GenosAI is designed to improve clinical trial decision-making by enabling pharmaceutical companies to analyze complex data, simplify trial-related queries, and expedite the selection of sites and principal investigators, thereby facilitating quicker and more strategic trial initiations. As a result, these factors are expected to drive substantial growth in the North American AI in clinical trials market throughout the 2025–2032 forecast period. To know more about why North America is leading the market growth in the AI in clinical trials market, get a snapshot of the AI in Clinical Trials Market Outlook AI in Clinical Trials Market Dynamics The AI in clinical trials market is experiencing significant growth, driven by advancements in artificial intelligence, machine learning, and data analytics. AI technologies are being increasingly adopted to streamline clinical trial processes, such as patient recruitment, data collection, and monitoring. AI-powered tools help researchers identify suitable candidates faster, reducing the time and costs associated with recruitment. Additionally, AI aids in personalized treatment regimens by analyzing large datasets to identify optimal patient profiles and predict outcomes more accurately. One of the major factors fueling the market's growth is the need for improving efficiency in clinical trials. AI facilitates real-time monitoring of patient health, enabling researchers to detect potential issues early and make data-driven decisions. By automating time-consuming tasks, AI reduces human error, improves trial design, and accelerates the pace of development for new therapies. This increased efficiency is especially critical as the pharmaceutical industry faces growing pressure to bring drugs to market quickly due to competitive pressures and a rising demand for novel treatments. Another key driver in the AI in clinical trials market is the increasing complexity of modern drug development. With more targeted therapies, such as immunotherapies and gene therapies, clinical trials require sophisticated designs to accommodate diverse patient populations and intricate treatment regimens. AI technologies, including predictive analytics and natural language processing, help streamline this complexity by analyzing vast datasets to uncover meaningful insights. This supports the creation of more robust trial designs and accelerates decision-making processes, ultimately reducing costs. Despite its advantages, the adoption of AI in clinical trials faces challenges, such as concerns around data privacy, regulatory compliance, and the need for skilled personnel. Healthcare data is highly sensitive, and regulatory bodies are still adapting to ensure AI tools meet the necessary standards for clinical use. Furthermore, while AI can greatly assist in data analysis, the technology still requires human oversight to interpret results and ensure that ethical guidelines are followed. Addressing these challenges will be crucial for widespread AI adoption and for realizing its full potential in clinical trials. Looking ahead, the AI in clinical trials market is expected to expand further with the integration of more advanced AI capabilities, including deep learning and real-time data integration from wearables and remote monitoring devices. As healthcare systems continue to digitize and AI technologies evolve, their use in clinical trials will likely become more ubiquitous, making trials faster, cheaper, and more effective. The market is poised for continued growth, with AI playing a pivotal role in shaping the future of clinical research. Get a sneak peek at the AI in clinical trials market dynamics @ AI in Clinical Trials Market Dynamics Analysis Report Metrics Details Coverage Global Study Period 2022–2032 AI in Clinical Trials Market CAGR ~12% AI in Clinical Trials Market Size by 2032 USD 3.3 Billion Key AI in Clinical Trials Companies TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, among others AI in Clinical Trials Market Assessment AI in Clinical Trials Market Segmentation AI in Clinical Trials Market Segmentation By Product: Software and Services AI in Clinical Trials Market Segmentation By Technology: Machine Learning (ML), Natural Language Processing (NLP), and Others AI in Clinical Trials Market Segmentation By Application: Clinical Trial Design & Optimization, Patient Identification & Recruitment, Site Identification & Trial Monitoring, and Others AI in Clinical Trials Market Segmentation By Therapeutic Area: Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others AI in Clinical Trials Market Segmentation By End-User: Pharmaceutical & Biotechnology Companies and Medical Device Companies AI in Clinical Trials Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the AI in clinical trials market are set to emerge as the trendsetter explore @ AI in Clinical Trials Companies Table of Contents 1 AI in Clinical Trials Market Report Introduction 2 AI in Clinical Trials Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 AI in Clinical Trials Market Key Factors Analysis 6 AI in Clinical Trials Market Porter's Five Forces Analysis 7 AI in Clinical Trials Market Layout 8 AI in Clinical Trials Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the AI in clinical trials market by 2032? Click to get a snapshot of the AI in Clinical Trials Market Trends Related Reports Artificial Intelligence in Drug Commercialization Market Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others. Artificial Intelligence in Precision Medicine Market Artificial Intelligence in Precision Medicine Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in precision medicine companies, including TEMPUS, GE HealthCare, Envisionit Deep AI (Pty) Ltd., Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others. Artificial Intelligence In Drug Discovery Market Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others. Artificial Intelligence in Medical Imaging Market Artificial Intelligence in Medical Imaging Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical imaging companies, including Microsoft, Siemens Healthineers, GE Healthcare, NVIDIA Corporation, Philips Healthcare, Arterys, Butterfly Network, Enlitic, HeartFlow, Digital Diagnostics, among others. Artificial Intelligence in Life Sciences Market Artificial Intelligence in Life Sciences Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in life sciences companies, including IBM Corporation, Atomwise, Inc., Nuance Communications, Inc., NuMedii, Inc., AiCure LLC, APIXIO, Inc., Insilico Medicine, Inc., Enlitic, Inc., Sensely, Inc., Zebra Medical Vision, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
